Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation.

ABSTRACT: Chronic myeloid leukemia (CML) usually requires long-term therapy with tyrosine kinase inhibitors (TKIs). While these agents have markedly advanced the clinical management and prognosis of CML, a subset of patients experience treatment resistance or suboptimal response, necessitating multiple lines of TKI therapy. Few treatment options exist for patients who are resistant or intolerant to first- and second-line therapies. To provide guidance for the management of patients in chronic-phase failing at least two lines of treatment, a literature review followed by consensus generation from an expert panel with a modified Delphi process was conducted. This was followed by a meeting in person and subsequent online iterations for the establishment of a list of consensus guidelines. Consensus was

SUBMITTER: Cheung CYM 

PROVIDER: S-EPMC12283482 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature